Compare Gilead Sciences, Inc. (GILD) vs Herbalife Nutrition Ltd (HLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Herbalife Nutrition Ltd — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Herbalife Nutrition Ltd trades at $13.03 (market cap $1.34B). The key difference: Gilead Sciences, Inc. is far larger — about 136.1× Herbalife Nutrition Ltd's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Herbalife Nutrition Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Herbalife Nutrition Ltd for 43 Days on average.
| GILD | HLF | |
|---|---|---|
Market Cap | $182.40B | $1.34B |
Volume | 4,469,821 | 1,589,457 |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $19.96 |
52-Week Low | $116.74 | $7.75 |
Typical Hold Time | 111 Days | 43 Days |
Enterprise Value | $205.46B | $3.18B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.
Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.
Herbalife (HLF) trades at $13.03, up 3.0% with a bullish technical signal. The stock shows attractive valuation metrics with P/E of 8.22 and P/S of 0.26, while maintaining strong gross margins of 77.7%. Recent Q1 2026 earnings beat expectations, though Q2 2026 missed. The company announced a $250 million share repurchase program and CEO transition, with management reaffirming 2026 guidance. Cash flow trends show improvement with projected positive net cash flow of $50 million for 2026.
HLF presents a value opportunity with discounted valuation and improving debt profile, though execution risks remain. Analyst consensus targets $19.00 (53.8% upside) with 14 buy ratings. Key risks include mixed earnings performance, high debt levels despite recent reduction, and leadership transition. The stock offers potential for re-rating if management delivers on margin expansion and growth targets outlined in recent investor presentations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →
